8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 9, 2026·SEC
Cartesian Therapeutics, Inc.(RNAC)Earnings, Financials & Key Ratios
RNAC•NASDAQ
Price updated Jun 19, 2026
AboutSelecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Show more
- Revenue$3M-92.8%
- EBITDA-$87M-102.8%
- Net Income-$130M-68.3%
- EPS (Diluted)-5.02-52.6%
- Gross Margin100%
- EBITDA Margin-3099.93%-2722.0%
- Operating Margin-3099.93%-2648.0%
- Net Margin-4658.63%-2241.4%
RNAC Key Insights
Cartesian Therapeutics, Inc. (RNAC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 86 (top 14%)
✗Weaknesses
- ✗Profits declining 13.6% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 30.0% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RNAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNAC Price & Volume
Cartesian Therapeutics, Inc. (RNAC) stock price & volume — 10-year historical chart
Loading chart...
RNAC Growth Metrics
Cartesian Therapeutics, Inc. (RNAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-7.37%
5 Years-29.96%
3 Years-70.66%
TTM-94.81%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-296.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-325.69%
Return on Capital
10 Years-56.54%
5 Years-15.39%
3 Years-28.1%
Last Year-25%
RNAC Recent Earnings
Cartesian Therapeutics, Inc. (RNAC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.46-73.8%
$0.84
Rev
$78,000-64.5%
$219,800
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$1.38-68.3%
$0.82
Rev
$947,000+529.9%
$150,333
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.38-70.4%
$0.81
Rev
$452,000+351.0%
$100,220
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.50+165.8%
$0.76
Rev
$298,000+67.8%
$177,560
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.46vs $0.84-73.8% | $78,000vs $219,800-64.5% |
| Q2 2026 | Mar 9, 2026 | $1.38vs $0.82-68.3% | $947,000vs $150,333+529.9% |
| Q4 2025 | Nov 6, 2025 | $1.38vs $0.81-70.4% | $452,000vs $100,220+351.0% |
| Q3 2025 | Aug 7, 2025 | $0.50vs $0.76+165.8% | $298,000vs $177,560+67.8% |
Based on last 12 quarters of dataView full earnings history →
RNAC Peer Comparison
Cartesian Therapeutics, Inc. (RNAC) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 LEGN | 5.17B | 27.93 | -17.46 | 64.04% | -21.97% | -24.91% | 0.41 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare RNAC vs Peers
Cartesian Therapeutics, Inc. (RNAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNAC Income Statement
Cartesian Therapeutics, Inc. (RNAC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 207K | 903K | 6.68M | 16.6M | 85.08M | 110.78M | 26M | 38.91M | 2.8M | 1.77M |
Revenue Growth % | -97.44% | 336.23% | 639.42% | 148.57% | 412.6% | 30.21% | -76.53% | 49.64% | -92.81% | -94.81% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 2.04M | 0 | 0 | 0 | 12.8M |
COGS % of Revenue | - | - | - | - | - | 1.84% | - | - | - | - |
Gross Profit | 207K▲ 0% | 903K▲ 336.2% | 6.68M▲ 639.4% | 16.6M▲ 148.6% | 85.08M▲ 412.6% | 108.74M▲ 27.8% | 26M▼ 76.1% | 38.91M▲ 49.6% | 2.8M▼ 92.8% | -11.02M▲ 0% |
Gross Margin % | 100% | 100% | 100% | 100% | 100% | 98.16% | 100% | 100% | 100% | -620.96% |
Gross Profit Growth % | -97.44% | 336.23% | 639.42% | 148.57% | 412.6% | 27.81% | -76.09% | 49.64% | -92.81% | - |
Operating Expenses | 63.24M | 64.95M | 59.13M | 73.42M | 89.67M | 94.2M | 112.42M | 82.81M | 89.5M | 80.29M |
OpEx % of Revenue | 30551.21% | 7192.69% | 885.61% | 442.36% | 105.4% | 85.04% | 432.32% | 212.81% | 3199.93% | - |
Selling, General & Admin | 18.08M | 17.26M | 16.39M | 18.91M | 20.94M | 23.86M | 40.45M | 30.13M | 31.47M | 30.27M |
SG&A % of Revenue | 8732.37% | 1911.74% | 245.45% | 113.95% | 24.61% | 21.54% | 155.55% | 77.42% | 1125.06% | - |
Research & Development | 45.16M | 47.69M | 42.74M | 54.51M | 68.74M | 72.38M | 71.26M | 45.1M | 58.03M | 62.82M |
R&D % of Revenue | 21818.84% | 5280.95% | 640.15% | 328.4% | 80.79% | 65.34% | 274.03% | 115.91% | 2074.87% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -2.04M | 710K | 7.58M | 0 | -1000K |
Operating Income | -63.78M▲ 0% | -65.02M▼ 1.9% | -52.45M▲ 19.3% | -56.82M▼ 8.3% | -4.6M▲ 91.9% | 14.54M▲ 416.2% | -86.42M▼ 694.4% | -43.9M▲ 49.2% | -86.7M▼ 97.5% | -91.31M▲ 0% |
Operating Margin % | -30813.53% | -7200.66% | -785.61% | -342.36% | -5.4% | 13.12% | -332.32% | -112.81% | -3099.93% | -5144.51% |
Operating Income Growth % | -83.97% | -1.94% | 19.33% | -8.32% | 91.91% | 416.25% | -694.41% | 49.2% | -97.52% | - |
EBITDA | -63.03M | -64.05M | -50.43M | -55.09M | -2.88M | 16.57M | -85.57M | -42.75M | -86.7M | -90.12M |
EBITDA Margin % | -30451.21% | -7092.69% | -755.25% | -331.95% | -3.38% | 14.96% | -329.08% | -109.85% | -3099.93% | -5077.18% |
EBITDA Growth % | -86.12% | -1.61% | 21.26% | -9.25% | 94.78% | 675.92% | -616.28% | 50.05% | -102.84% | -79.12% |
D&A (Non-Cash Add-back) | 750K | 975K | 2.03M | 1.73M | 1.72M | 2.04M | 843K | 1.15M | 0 | 1.2M |
EBIT | -64.11M | -63.84M | -53.83M | -67.32M | -6.88M | 37.8M | -235.88M | -77.14M | -86.7M | -68.45M |
Net Interest Income | -1.21M | -1.49M | -1.52M | -1.56M | -2.84M | -3.03M | 2.13M | 7.39M | 6.58M | 5.59M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 4.96M | 7.39M | 6.58M | 5.59M |
Interest Expense | 1.21M | 1.49M | 1.52M | 1.56M | 2.84M | 3.03M | 2.83M | 0 | 0 | 0 |
Other Income/Expense | -1.54M | -314K | -2.9M | -12.05M | -5.12M | 20.23M | -152.29M | -33.24M | -52.79M | -69.65M |
Pretax Income | -65.32M▲ 0% | -65.34M▼ 0.0% | -55.35M▲ 15.3% | -68.88M▼ 24.4% | -9.72M▲ 85.9% | 34.77M▲ 457.7% | -238.71M▼ 786.5% | -77.14M▲ 67.7% | -139.5M▼ 80.8% | -160.97M▲ 0% |
Pretax Margin % | -31556.04% | -7235.44% | -828.97% | -414.99% | -11.43% | 31.39% | -917.97% | -198.23% | -4987.31% | -9068.56% |
Income Tax | 0 | 0 | 0 | 0 | 15.97M | -609K | -19M | 287K | -9.19M | -9.19M |
Effective Tax Rate % | 0% | 0% | 0% | 0% | -164.24% | -1.75% | 7.96% | -0.37% | 6.59% | 5.71% |
Net Income | -65.32M▲ 0% | -65.34M▼ 0.0% | -55.35M▲ 15.3% | -68.88M▼ 24.4% | -25.69M▲ 62.7% | 35.38M▲ 237.7% | -219.71M▼ 721.0% | -77.42M▲ 64.8% | -130.3M▼ 68.3% | -151.77M▲ 0% |
Net Margin % | -31556.04% | -7235.44% | -828.97% | -414.99% | -30.19% | 31.94% | -844.91% | -198.97% | -4658.63% | -8550.65% |
Net Income Growth % | -80.39% | -0.02% | 15.28% | -24.44% | 62.71% | 237.73% | -721.02% | 64.76% | -68.3% | -296.17% |
Net Income (Continuing) | -65.32M | -65.34M | -55.35M | -68.88M | -25.69M | 35.38M | -219.71M | -77.42M | -130.3M | -151.77M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -95.94▲ 0% | -87.55▲ 8.7% | -36.46▲ 58.4% | -20.42▲ 44.0% | -6.60▲ 67.7% | 3.00▲ 145.5% | -49.76▼ 1758.7% | -3.29▲ 93.4% | -5.02▼ 52.6% | -5.65▲ 0% |
EPS Growth % | 7.32% | 8.74% | 58.36% | 43.99% | 67.68% | 145.45% | -1758.67% | 93.39% | -52.58% | -325.69% |
EPS (Basic) | -95.94 | -87.55 | -36.46 | -20.42 | -6.74 | 7.33 | -49.76 | -2.99 | -5.02 | - |
Diluted Shares Outstanding | 567.36K | 621.92K | 1.27M | 2.81M | 3.18M | 4.05M | 5.17M | 23.69M | 25.97M | 26.86M |
Basic Shares Outstanding | 567.36K | 621.92K | 1.27M | 2.81M | 3.18M | 4.02M | 5.17M | 25.91M | 25.97M | 26.86M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RNAC Balance Sheet
Cartesian Therapeutics, Inc. (RNAC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 98.68M | 42.08M | 96.67M | 151.34M | 144.44M | 148.14M | 90.73M | 216.63M | 129.28M | 122.04M |
Cash & Short-Term Investments | 96.64M | 37.4M | 90.17M | 138.69M | 128.06M | 134.6M | 76.91M | 212.61M | 125.14M | 118.64M |
Cash Only | 70.7M | 37.4M | 90.17M | 138.69M | 114.06M | 106.44M | 76.91M | 212.61M | 125.14M | 118.64M |
Short-Term Investments | 25.94M | 0 | 0 | 0 | 14M | 28.16M | 0 | 0 | 0 | 0 |
Accounts Receivable | 63K | 0 | 5M | 7.22M | 9.91M | 9.86M | 8.85M | 872K | 1.11M | 261K |
Days Sales Outstanding | 111.09 | - | 273.33 | 158.87 | 42.53 | 32.48 | 124.24 | 8.18 | 145.5 | 126.05 |
Inventory | -2.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.98M | 0 | 0 | 0 | 0 | 3.68M | 4.97M | 3.14M | 3.02M | 3.14M |
Total Non-Current Assets | 2.42M | 2.41M | 2.9M | 14.09M | 15.44M | 17.75M | 214.32M | 218.4M | 167.13M | 166.35M |
Property, Plant & Equipment | 2.09M | 2.13M | 1.52M | 12.34M | 11.97M | 14.41M | 12.18M | 15.45M | 17.79M | 17M |
Fixed Asset Turnover | 0.10x | 0.42x | 4.38x | 1.34x | 7.11x | 7.69x | 2.13x | 2.52x | 0.16x | 0.10x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 48.16M | 48.16M | 48.16M | 48.16M |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 150.6M | 150.6M | 0 | 93.9M |
Long-Term Investments | 0 | 279K | 1.38M | 0 | 2M | 2M | 2M | 2M | 1.74M | 7.47M |
Other Non-Current Assets | 329K | 0 | 0 | 1.75M | 1.47M | 1.34M | 1.38M | 2.19M | 99.45M | 5.55M |
Total Assets | 101.1M▲ 0% | 44.48M▼ 56.0% | 99.57M▲ 123.8% | 165.44M▲ 66.2% | 159.88M▼ 3.4% | 165.89M▲ 3.8% | 305.05M▲ 83.9% | 435.02M▲ 42.6% | 296.41M▼ 31.9% | 288.39M▲ 0% |
Asset Turnover | 0.00x | 0.02x | 0.07x | 0.10x | 0.53x | 0.67x | 0.09x | 0.09x | 0.01x | 0.01x |
Asset Growth % | 13.21% | -56% | 123.84% | 66.15% | -3.36% | 3.75% | 83.89% | 42.61% | -31.86% | -67.69% |
Total Current Liabilities | 10.97M | 35.14M | 34.94M | 81.55M | 72.25M | 25.08M | 68.21M | 22.98M | 14.94M | 15.95M |
Accounts Payable | 1.61M | 1.1M | 500K | 443K | 224K | 316K | 3.15M | 288K | 1.29M | 1.6M |
Days Payables Outstanding | - | - | - | - | - | 56.62 | - | - | - | 39.68 |
Short-Term Debt | 0 | 21.39M | 18.91M | 0 | 5.96M | 8.48M | 0 | 0 | 4.15M | 4.19M |
Deferred Revenue (Current) | 787K | 959K | 1.67M | 72.05M | 53.88M | 593K | 2.31M | 0 | 0 | 0 |
Other Current Liabilities | 72K | 9.2M | 0 | 0 | 0 | 0 | 56.19M | 19.84M | 9.5M | 10.16M |
Current Ratio | 8.99x | 1.20x | 2.77x | 1.86x | 2.00x | 5.91x | 1.33x | 9.43x | 8.65x | 7.65x |
Quick Ratio | 9.18x | 1.20x | 2.77x | 1.86x | 2.00x | 5.91x | 1.33x | 9.43x | 8.65x | 7.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 86.37 |
Total Non-Current Liabilities | 38.31M | 14.76M | 56.23M | 101.89M | 65.11M | 46.98M | 677.02M | 418.85M | 407.71M | 420.56M |
Long-Term Debt | 21.04M | 0 | 0 | 24.79M | 19.67M | 17.79M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 9.65M | 8.6M | 10.05M | 8.79M | 11.13M | 8.53M | 34.48M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 322.08M | 16.14M | 6.95M | 30.04M |
Other Non-Current Liabilities | 1.35M | 938K | 41.55M | 28.71M | 25.42M | 19.14M | 342.62M | 391.57M | 392.24M | 405.95M |
Total Liabilities | 49.29M | 49.9M | 91.17M | 183.44M | 137.36M | 72.06M | 745.23M | 441.82M | 422.65M | 436.51M |
Total Debt | 21.04M | 21.39M | 19.28M | 35.35M | 35.28M | 37.92M | 10.96M | 13.98M | 12.68M | 11.86M |
Net Debt | -49.66M | -16.02M | -70.89M | -103.34M | -78.78M | -68.51M | -65.96M | -198.63M | -112.46M | -106.79M |
Debt / Equity | 0.41x | - | 2.30x | - | 1.57x | 0.40x | - | - | - | -0.08x |
Debt / EBITDA | - | - | - | - | - | 2.29x | - | - | - | -0.13x |
Net Debt / EBITDA | - | - | - | - | - | -4.13x | - | - | - | 1.18x |
Interest Coverage | -53.16x | -42.73x | -35.44x | -43.26x | -2.42x | 12.47x | -83.26x | - | - | - |
Total Equity | 51.81M▲ 0% | -5.42M▼ 110.5% | 8.4M▲ 255.0% | -18.01M▼ 314.4% | 22.52M▲ 225.1% | 93.83M▲ 316.6% | -440.18M▼ 569.1% | -6.8M▲ 98.5% | -126.24M▼ 1755.9% | -148.12M▲ 0% |
Equity Growth % | -5.72% | -110.46% | 254.98% | -314.43% | 225.07% | 316.62% | -569.14% | 98.45% | -1755.92% | -7104.69% |
Book Value per Share | 91.32 | -8.71 | 6.64 | -6.41 | 7.09 | 23.16 | -85.14 | -0.29 | -4.86 | -5.52 |
Total Shareholders' Equity | 51.81M | -5.42M | 8.4M | -18.01M | 22.52M | 93.83M | -440.18M | -6.8M | -126.24M | -148.12M |
Common Stock | 3K | 3K | 9K | 11K | 12K | 15K | 16K | 3K | 3K | 3K |
Retained Earnings | -216.9M | -280.4M | -335.75M | -404.63M | -430.32M | -394.94M | -614.65M | -692.07M | -822.37M | -861.55M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -4.42M | -4.56M | -4.52M | -4.56M | -4.57M | -4.56M | -4.6M | -4.62M | -4.58M | -4.58M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAC Cash Flow Statement
Cartesian Therapeutics, Inc. (RNAC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -52.04M | -59.16M | -51.44M | 34.88M | -60.38M | -31.63M | -51.16M | -23.67M | -73.94M | -72.97M |
Operating CF Margin % | -25138.65% | -6551.61% | -770.33% | 210.16% | -70.97% | -28.55% | -196.74% | -60.84% | -2643.58% | - |
Operating CF Growth % | -164.38% | -13.69% | 13.06% | 167.82% | -273.11% | 47.62% | -61.74% | 53.73% | -212.33% | -383.98% |
Net Income | -65.32M | -65.34M | -55.35M | -68.88M | -25.69M | 35.38M | -219.71M | -77.42M | -130.3M | -151.77M |
Depreciation & Amortization | 750K | 975K | 2.03M | 734K | 1.25M | 1.29M | 843K | 1.15M | 2.96M | 2.42M |
Stock-Based Compensation | 0 | 0 | 0 | 5.42M | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M | 10.44M |
Deferred Taxes | 0 | 0 | 0 | 0 | 2.4M | -21.4M | -19M | 287K | -9.19M | -9.19M |
Other Non-Cash Items | 9.09M | 8.45M | 6.37M | 12.6M | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M | 76.06M |
Working Capital Changes | 7.12M | -781K | -4.48M | 85M | -48.19M | -60.38M | 4.97M | -5.79M | -8.06M | -913K |
Change in Receivables | 152K | 0 | -5M | -2.22M | -2.69M | 3.32M | 907K | 7.98M | -243K | 1.5M |
Change in Inventory | 0 | 0 | 0 | 0 | 211K | 920K | 0 | 0 | 0 | 0 |
Change in Payables | -2.33M | -516K | -600K | -57K | -219K | 92K | 2.83M | -2.93M | 1.07M | -443K |
Cash from Investing | -2.1M | 25.27M | 229K | -741K | -17.14M | -15M | 34.61M | -8.74M | -5.45M | -4.41M |
Capital Expenditures | -733K | -884K | -47K | -815K | -1.08M | -1.2M | -206K | -9.09M | -5.45M | -4.41M |
CapEx % of Revenue | 354.11% | 97.9% | 0.7% | 4.91% | 1.28% | 1.08% | 0.79% | 23.37% | 194.99% | 248.23% |
Acquisitions | 4K | 99K | 122K | 0 | 0 | 0 | 6.56M | 351K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 74K | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 66.02M | 697K | 105.04M | 14.43M | 52.9M | 39.22M | -13.14M | 168.43M | -8.05M | 15.64M |
Debt Issued (Net) | 8.02M | 0 | -2.8M | 5.42M | 0 | 0 | -27.46M | 0 | 0 | 0 |
Equity Issued (Net) | 57.11M | 0 | 37.66M | 12.38M | 51.96M | 38.98M | 14.08M | 164.44M | -301K | 15.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -6.17M | 0 | 0 | 0 |
Other Financing | 886K | 697K | 70.18M | -3.37M | 939K | 235K | 231K | 3.99M | -7.75M | -38K |
Net Change in Cash | 11.96M▲ 0% | -33.3M▼ 378.3% | 52.77M▲ 258.5% | 48.51M▼ 8.1% | -24.63M▼ 150.8% | -7.4M▲ 70.0% | -29.75M▼ 302.1% | 135.99M▲ 557.1% | -87.41M▼ 164.3% | -61.73M▲ 0% |
Free Cash Flow | -52.77M▲ 0% | -60.05M▼ 13.8% | -51.48M▲ 14.3% | 34.07M▲ 166.2% | -61.47M▼ 280.4% | -32.83M▲ 46.6% | -51.37M▼ 56.5% | -32.77M▲ 36.2% | -79.39M▼ 142.3% | -77.37M▲ 0% |
FCF Margin % | -25492.75% | -6649.5% | -771.03% | 205.25% | -72.25% | -29.64% | -197.53% | -84.21% | -2838.58% | -4359.1% |
FCF Growth % | -160.35% | -13.79% | 14.26% | 166.17% | -280.44% | 46.59% | -56.45% | 36.21% | -142.3% | -91.37% |
FCF per Share | -93.01 | -96.55 | -40.69 | 12.12 | -19.35 | -8.10 | -9.93 | -1.38 | -3.06 | -2.88 |
FCF Conversion (FCF/Net Income) | 0.80x | 0.91x | 0.93x | -0.51x | 2.35x | -0.89x | 0.23x | 0.31x | 0.57x | 0.51x |
Interest Paid | 0 | 0 | 0 | 1.02M | 0 | 0 | 1.85M | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNAC Key Ratios
Cartesian Therapeutics, Inc. (RNAC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -122.36% | -281.65% | -3716.01% | - | -1137.85% | 60.82% | - | - | - | 194.13% |
Return on Invested Capital (ROIC) | -910.94% | - | - | - | - | 43.07% | - | - | - | 33.83% |
Gross Margin | 100% | 100% | 100% | 100% | 100% | 98.16% | 100% | 100% | 100% | -620.96% |
Net Margin | -31556.04% | -7235.44% | -828.97% | -414.99% | -30.19% | 31.94% | -844.91% | -198.97% | -4658.63% | -8550.65% |
Debt / Equity | 0.41x | - | 2.30x | - | 1.57x | 0.40x | - | - | - | -0.08x |
Interest Coverage | -53.16x | -42.73x | -35.44x | -43.26x | -2.42x | 12.47x | -83.26x | - | - | - |
FCF Conversion | 0.80x | 0.91x | 0.93x | -0.51x | 2.35x | -0.89x | 0.23x | 0.31x | 0.57x | 0.51x |
Revenue Growth | -97.44% | 336.23% | 639.42% | 148.57% | 412.6% | 30.21% | -76.53% | 49.64% | -92.81% | -94.81% |
Related:RNAC Dividend History·RNAC Revenue History·RNAC Price History·RNAC P/E History·RNAC Financial Ratios·RNAC Institutional Holders
RNAC SEC Filings & Documents
Cartesian Therapeutics, Inc. (RNAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
RNAC Frequently Asked Questions
Cartesian Therapeutics, Inc. (RNAC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cartesian Therapeutics, Inc. (RNAC) reported $1.8M in revenue for fiscal year 2025. This represents a 42% decrease from $3.0M in 2014.
Cartesian Therapeutics, Inc. (RNAC) saw revenue decline by 92.8% over the past year.
Cartesian Therapeutics, Inc. (RNAC) reported a net loss of $151.8M for fiscal year 2025.
Dividend & Returns
Cartesian Therapeutics, Inc. (RNAC) had negative free cash flow of $77.4M in fiscal year 2025, likely due to heavy capital investments.